Hormonal
Weekly administration of semaglutide at 2.4 mg induces significant weight loss (mean 14.9%) and improves glycemic control (HbA1c < 7.0% in 57-74% of patients) in adults with obesity or type 2 diabetes, with effects proportional to dose and duration.
If you have obesity or type 2 diabetes, weekly semaglutide (2.4 mg for weight loss, 1-1.0 mg for diabetes) is a highly effective treatment that can lead to significant weight loss (up to 15%) and better blood sugar control. While nausea and vomiting are common side effects, they are usually mild and temporary, and weight loss often occurs regardless of whether you experience them. An oral version is also available if you prefer to avoid injections. Discuss this with your doctor to see if it's right for you.
Semaglutide administered once a week, particularly at a dosage of 2.4 mg, led to a significant mean weight loss of 14.9% compared to 2.4% in the group receiving a placebo... Research has indicated weight reductions between 3 and 15 kg, with greater doses and longer treatment durations, resulting in more substantial decreases. Additionally, semaglutide considerably improved glycemic control, with 57-74% of participants receiving 1.0 mg achieving HbA1c levels below 7.0%.
Why this rating
Based on a systematic review of 9 studies including RCTs, though some showed moderate bias risks.
Source
Semaglutide in Obesity and Type 2 Diabetes Management: A Systematic Review of Clinical Outcomes
Sri Ram Charan Gundapaneni et al. · Cureus · 2025
DOI 10.7759/cureus.78555
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →